NCT07360275

A Study of VCT220 in Participants With Hypertension and Obesity or Overweight

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of VCT220 in Participants With Hypertension and Obesity or Overweight.

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 160 (estimated)
• Sponsor: Vincentage Pharma Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to explore the safety and efficacy of VCT220 for the treatment of hypertension in participants with obesity or overweight.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	VCT220 Tablet	Administered orally, with or without food.
DRUG	VCT220 Placebo Tablet	Administered orally, with or without food.

Timeline

• Start date: 2026-03-01
• Primary completion: 2026-10-20
• Completion: 2026-12-20
• First posted: 2026-01-22
• Last updated: 2026-01-22

Locations

2 sites across 1 country: China